Stockreport

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

Viracta Therapeutics, Inc.  (VIRX) 
PDF Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrol [Read more]